Linked videos:
Finasteride and neurosteroids:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
Finasteride and dutasteride dosing:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]

Sources:
1. Gormley GJ, Stoner E, Bruskewitz RC, et al. The Effect of Finasteride in Men with Benign Prostatic Hyperplasia. New England Journal of Medicine. 1992;327(17):1185-1191. doi:10.1056/NEJM199210223271701
2. Faller B, Farley D, Nick H. Finasteride: a slow-binding 5 alpha-reductase inhibitor. Biochemistry. 1993;32(21):5705-5710. doi:10.1021/bi00072a028
3. Steiner JF. Clinical Pharmacokinetics and Pharmacodynamics of Finasteride: Clinical Pharmacokinetics. 1996;30(1):16-27. doi:10.2165/00003088-199630010-00002
4. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550-554.
5. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999;47(1):53-58. doi:10.1046/j.1365-2125.1999.00843.x
6. Steckelbroeck S, Watzka M, Reichelt R, et al. Characterization of the 5α-Reductase-3α-Hydroxysteroid Dehydrogenase Complex in the Human Brain1. The Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1324-1331. doi:10.1210/jcem.86.3.7325
7. Sullivan MJ, Geller J. The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia. BMC Urology. 2002;2(1):2. doi:10.1186/1471-2490-2-2
8. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor. The Journal of Clinical Endocrinology & Metabolism. 2004;89(5):2179-2184. doi:10.1210/jc.2003-030330
9. Tartagni M, Schonauer MM, Cicinelli E, et al. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertility and Sterility. 2004;82(3):752-755. doi:10.1016/j.fertnstert.2004.02.118
10. DHT rebound minimal after missed 5-ARI doses. Published September 1, 2004. Accessed January 3, 2024. [ Ссылка ]
11. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology. 2006;55(6):1014-1023. doi:10.1016/j.jaad.2006.05.007
12. Drury JE, Costanzo LD, Penning TM, Christianson DW. Inhibition of Human Steroid 5β-Reductase (AKR1D1) by Finasteride and Structure of the Enzyme-Inhibitor Complex *. Journal of Biological Chemistry. 2009;284(30):19786-19790. doi:10.1074/jbc.C109.016931
13. Pohlman GD, Pohlman EA, Crawford ED. Dutasteride: A Review of its Use in the Management of Prostate Disorders. Clinical Medicine Insights: Therapeutics. 2011;3:CMT.S1956. doi:10.4137/CMT.S1956
14. Kim KH, Park SM, Lee YJ, Sim WY, Lew BL. 16799 Similar efficacy of maintenance treatment of finasteride 1 mg every other month compared with finasteride 1 mg daily in Korean men with androgenetic alopecia after taking finasteride 1 mg daily for 1 year. Journal of the American Academy of Dermatology. 2020;83(6):AB185. doi:10.1016/j.jaad.2020.06.828

свернуть